Eutilex
Daeryung Technotown 17 Gasan digital 1-ro 25
Suite1401
Geumcheon-gu
Seoul
08594
Tel: 82-2-3402-7310
Fax: 82-2-3402-7399
Website: http://eutilex.com/
Email: partnering@eutilex.com
About Eutilex
Based in Seoul, South Korea, Eutilex is a clinical-stage biopharmaceutical company focused on the development of anti-tumor T cell and antibody therapeutics for the treatment of cancers and autoimmune diseases. The most advanced drug candidate is an adoptive T Cell therapy, which has finished Phase 1 clinical trials and will begin Phase 2. Other pipeline candidates in development include monoclonal antibodies, EU-101, EU-102 and EU-103.LEADERSHIP:
Founder and CEO: Byoung S. Kwon
JOBS:
Please click here for Eutilex job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
4 articles about Eutilex
-
Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST
9/7/2021
Therapeutic Solutions International, Inc., announced the signing of a memorandum of understanding with immunotherapy company Eutilogics, Inc., the wholly owned subsidiary of clinical stage Korean company, Eutilex Co., Ltd., based on exploring synergies between technologies of both Companies.
-
Eutilex and Huahai Enter Immuno-Oncology Partnership
11/6/2017
Under the agreement, Huahai takes a $30M equity stake in Eutilex and receives an exclusive license to develop and commercialize EU-101.
-
Eutilex Completes $18 Million Series A Financing to Advance Immuno-Oncology Programs
12/8/2016
-
Eutilex Names Agustin de la Calle Chief Business Officer
11/8/2016